Anti-nicotine abuse vaccines in the pipeline: an update

Bibliography

• Stead L, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146
   PubMed Web of Science ®Google Scholar
• Le Foll B, George TP. Treatment of tobacco dependence: integrating recent progress into practice. Can Med Assoc J 2007;177(11):1373-80
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. J Am Med Assoc 2006;296(1):64-71
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005;7(3):106-13
   PubMedGoogle Scholar
• Wu P, Wilson K, Dimoulas P, Mills EJ, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Pub Health 2006;6:300
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. J Am Med Assoc 2006;296(1):56-63
   PubMed Web of Science ®Google Scholar
• Schnoll RA, Patterson F, Lerman C. Treating tobacco dependence in women. J Womens Health (Larchmt) 2007;16(8):1211-8
   PubMed Web of Science ®Google Scholar
• Cytos Biotechnology AG. Company website. Schlieren: Cytos Biotechnology AG. Available from: www.cytos.ch [Last accessed December 2007]
   Google Scholar
• Nabi Biopharmaceuticals. Company website. Rockville, MD: Nabi Biopharmaceuticals. Available from: www.nabi.com [Last accessed December 2007]
   Google Scholar
• Celtic Pharma. Company website. Hamilton, Bermuda: Celtic Pharma. Available from: www.celticpharma.com [Last accessed December 2007]
   Google Scholar
• Maurer P, Bachmann MF. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs 2007;16(11):1775-83
   PubMed Web of Science ®Google Scholar
• Heading CE. Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction. Curr Opin Investig Drugs 2007;8(1):71-7
   PubMed Web of Science ®Google Scholar
• Dyer MR, Renner WA, Bachmann MF. A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today 2006;11(21-22):1028-33
   PubMed Web of Science ®Google Scholar
• Maurer P, Bachmann MF. Therapeutic vaccines for nicotine dependence. Curr Opin Mol Ther 2006;8(1):11-6
   PubMed Web of Science ®Google Scholar
• Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005;35(7):2031-40
   PubMed Web of Science ®Google Scholar
• Cerny T. Anti-nicotine vaccination: where are we? Recent Results Cancer Res 2005;166:167-75
   PubMedGoogle Scholar
• No authors listed. Trial watch. Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines 2004;3(4):386
   Google Scholar
• Goniewicz ML, Koszowski B, Czogala J, Zymelka A, et al. New prospects of nicotine dependence treatment: vaccines. Przegl Lek 2006;63(10):1114-8
   PubMedGoogle Scholar
• Heading CE. TA-CD: Xenova. IDrugs 2002;5(11):1070-4
   PubMedGoogle Scholar
• Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002;20(7-8):1196-204
   PubMed Web of Science ®Google Scholar
• Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58(2):158-64
   PubMed Web of Science ®Google Scholar
• Heading CE. NicVAX: Nabi Biopharmaceuticals. IDrugs 2003;6(12):1178-81
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005;78(5):456-67
   PubMed Web of Science ®Google Scholar
• Sanderson SD, Cheruku SR, Padmanilayam MP, et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 2003;3(1):137-46
   PubMed Web of Science ®Google Scholar
• Carrera MR, Ashley JA, Hoffman TZ, et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 2004;12(3):563-70
   PubMed Web of Science ®Google Scholar
• Meijler MM, Matsushita M, Altobell LJ, 3rd, et al. A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc 2003;125(24):7164-5
   PubMed Web of Science ®Google Scholar
• Dickerson TJ, Yamamoto N, Janda KD. Antibody-catalyzed oxidative degradation of nicotine using riboflavin. Bioorg Med Chem 2004;12(18):4981-7
   PubMed Web of Science ®Google Scholar
• de Villiers SH, Lindblom N, Kalayanov G, et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002;69(3):247-53
   PubMed Web of Science ®Google Scholar
• Lindblom N, de Villiers SH, Kalayanov G, et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002;69(3):254-60
   PubMed Web of Science ®Google Scholar
• Cho CH, Purohit V. Alcohol tobacco and cancer. Karger, Basel/New York; 2006
   Google Scholar
• Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2004;30(4):344-45
   PubMed Web of Science ®Google Scholar
• Cerny T, Cerny EH: Reply to: Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 2005;31(9):558
   PubMedGoogle Scholar
• Cerny EH, Levy R, Mauel J, et al. Preclinical development of a vaccine ‘against smoking’. Onkologie 2002;25(5):406-11
   PubMed Web of Science ®Google Scholar